Search Results

Your search for Prudence Francis, MD, and Hope Rugo, MD,Prudence Francis, MD, and Hope Rugo, MD matches 2 pages

Showing 1 - 2

By Prudence Francis, MD, and Hope Rugo, MD / 2014 San Antonio Breast Cancer Symposium

Prudence Francis, MD, and Hope Rugo, MD, on the Phase III SOFT Trial

Prudence Francis, MD, of Peter MacCallum Cancer Centre, and Hope Rugo, MD, of the University of California, San Francisco, discuss data from abstract S3-08, "Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone...

breast cancer

By Alice Goodman / January 25, 2015

Ovarian Suppression Plus Hormonal Therapy May Be Practice-Changing in Premenopausal Hormone Receptor–Positive Early-Stage Breast Cancer

Results of the large International Breast Cancer Study Group (IBCSG)-coordinated SOFT trial present a convincing argument for the addition of ovarian function suppression to adjuvant hormonal therapy to reduce the risk of tumor recurrence in younger women with hormone receptor–positive early-stage...

Apr

Today In Oncology

Search Results

Your search for Prudence Francis, MD, and Hope Rugo, MD,Prudence Francis, MD, and Hope Rugo, MD matches 2 pages

Prudence Francis, MD, and Hope Rugo, MD, on the Phase III SOFT Trial

Ovarian Suppression Plus Hormonal Therapy May Be Practice-Changing in Premenopausal Hormone Receptor–Positive Early-Stage Breast Cancer

Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care

Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being

FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs

AI Model May Help Predict Treatment Responses Select Most Effective Cancer Therapies in Patients With Cancer

In-Hospital Mortality Among Patients With COVID-19 Infection, With or Without Cancer